Tranexamic acid in a mouse model of cerebral amyloid angiopathy: setting the stage for a novel stroke treatment approach

CONCLUSION: Long-term TXA treatment does not alter brain Aβ levels or impact neurologic behavior in mice predisposed to amyloid deposition and had minor effects on the levels of inflammatory mediators. This finding supports the safety of TXA and lays the foundation for TXA as a novel treatment to reduce sICH in patients with CAA.PMID:37694270 | PMC:PMC10483050 | DOI:10.1016/j.rpth.2023.102166

Source: Thrombosis and Haemostasis - September 11, 2023 Category: Hematology Authors: Zikou Liu Fiona M McCutcheon Heidi Ho Joanne Chia Yunxin Xiao Isabel Tippett Charithani B Keragala Geoffrey C Cloud Robert L Medcalf Source Type: research